H. pylori: How Probiotics & Mastic Gum Pair With Standard Triple Therapy

Helicobacter pylori is one of the most common chronic bacterial infections in the world — an estimated half the global population carries it, often without knowing. It’s also the leading infectious cause of peptic ulcers and a recognized risk factor for stomach cancer, which is why guideline-directed eradication matters. The role of probiotics and mastic gum is supportive, not curative — here’s what the research says about adjunct strategies alongside the antibiotic regimens that do the heavy lifting.

The short answer

H. pylori eradication is a medical job. Specific probiotic strains — Lactobacillus reuteri DSMZ 17648, L. johnsonii La1, and Saccharomyces boulardii — have peer-reviewed research showing they can improve eradication rates and reduce antibiotic side effects when used alongside standard triple or quadruple therapy. Mastic gum has small-trial data suggesting activity against H. pylori but is a supportive nutrient, not a substitute for antibiotics. The most under-appreciated role for a quality probiotic is after the antibiotic course — rebuilding the gut microbiome is where multi-strain formulations earn their keep. Anyone with confirmed or suspected H. pylori needs a gastroenterologist, not a supplement strategy alone.

What H. pylori actually is

Helicobacter pylori is a spiral-shaped bacterium that colonizes the mucous layer of the stomach lining. It’s one of the few organisms that can survive the stomach’s acidity long-term, which it does by producing urease (an enzyme that neutralizes acid locally) and burrowing into the protective mucus layer. Most people acquire it in childhood, often from family members, and once colonized it can persist for decades.

The Maastricht VI/Florence Consensus (2022) estimates that roughly half the global population carries H. pylori, with prevalence varying by region and age. The majority of carriers never develop overt disease — but H. pylori is the leading infectious cause of peptic ulcer disease, accounts for most non-NSAID gastric ulcers, and is classified by the WHO as a Group 1 carcinogen for gastric cancer. It’s also implicated in MALT lymphoma and a subset of non-ulcer dyspepsia.

Symptoms, when present, are non-specific: dull or burning upper-abdominal pain, nausea, bloating, early satiety, and sometimes melena if an ulcer is bleeding. Many people have no symptoms and only discover the infection during workup for another reason — which is why testing belongs in the hands of a clinician who can interpret results in context.

Standard medical eradication

Eradication of H. pylori is a multi-drug antibiotic regimen prescribed and supervised by a gastroenterologist. There is no credible natural protocol that replaces this. Both the American College of Gastroenterology (Chey et al., 2017) and the Maastricht VI/Florence Consensus (2022) lay out first-line and salvage regimens that vary by region based on local clarithromycin resistance patterns.

The most common regimens in current guidelines:

• Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) — increasingly first-line in high-resistance regions, 10–14 days.
• Clarithromycin triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) — the historical standard, still appropriate in low-resistance regions, 14 days.
• Concomitant therapy (PPI + clarithromycin + amoxicillin + nitroimidazole) — 10–14 days.
• Levofloxacin-based salvage regimens — second- or third-line after failure.

Eradication rates hover in the 80–90% range when patients complete the full course. Failures happen, often due to resistance or incomplete adherence — which is why side-effect tolerability matters and why probiotic adjuncts have been studied so intensively. Never skip, shorten, or substitute the antibiotic regimen on your own. Incomplete eradication encourages resistance and leaves the infection in place.

The probiotic research

Probiotic research in the H. pylori context breaks into two practical buckets: certain strains appear to reduce H. pylori load directly through co-aggregation and competition, and others primarily improve tolerability of antibiotic therapy. Wang and colleagues’ 2013 meta-analysis in the World Journal of Gastroenterology pooled multiple randomized trials and concluded that adjunctive probiotics modestly improved eradication rates and meaningfully reduced antibiotic-associated side effects.

The strains with the strongest direct evidence:

• Lactobacillus reuteri DSMZ 17648. Mehling and Busjahn’s 2013 study in Nutrients reported a reduction in H. pylori load through a co-aggregation mechanism — the strain physically binds to H. pylori and the complex is cleared. Strain specificity matters; not all L. reuteri strains share this property.
• Lactobacillus johnsonii La1. One of the earlier probiotic strains studied directly against H. pylori, with research suggesting it can suppress bacterial activity and improve gastritis markers alongside standard therapy.
• Saccharomyces boulardii. A beneficial yeast, unaffected by antibiotics. McFarland’s 2015 meta-analysis in BMJ Open concluded that S. boulardii added to eradication regimens significantly reduced antibiotic-associated diarrhea and modestly improved eradication rates.

The honest framing: probiotics don’t eradicate H. pylori on their own. They are an adjunct that improves the experience and outcomes of standard therapy. The Maastricht VI guideline acknowledges this and notes that selected probiotics can be considered alongside eradication regimens — while explicitly preserving the antibiotic regimen as the primary intervention.

Mastic gum — what the trials show

Mastic gum is the resin of the Pistacia lentiscus tree, harvested for thousands of years on the Greek island of Chios. Modern research has investigated it for upper-GI applications including H. pylori.

The trials worth knowing:

• Huwez et al. (NEJM, 1998). A letter to the editor in the New England Journal of Medicine reported that low doses of mastic gum healed duodenal ulcers and showed H. pylori activity in vitro. Small and limited, but it kicked off modern research interest.
• Dabos et al. (Phytomedicine, 2010). A randomized pilot study evaluating mastic gum against H. pylori in 52 patients. The trial reported a modest eradication signal with mastic monotherapy — lower than antibiotic regimens, but biologically meaningful.
• Loughlin et al. (J Antimicrob Chemother, 2003). An in vitro study testing mastic against multiple H. pylori isolates, finding strain-dependent susceptibility and modest activity at clinically achievable concentrations.

The fair summary: mastic gum has a real but modest evidence base for upper-GI comfort and some H. pylori activity in small trials. It is not a replacement for antibiotic eradication. It’s a reasonable supportive nutrient with traditional use behind it and meaningful (if early) modern research — which is why we built mastic gum into Complete Gut Defense as part of upper-GI support, not as a treatment for H. pylori.

Stacking with eradication therapy

The practical question for anyone going through eradication therapy: how do supplements fit alongside? The evidence-grounded approach, always discussed with the prescribing doctor first:

1. Don’t skip or shorten the antibiotic regimen. Adherence is the single biggest predictor of eradication success. Missing doses encourages resistance.
2. Take probiotics on a separate schedule from antibiotics — separate by at least 2 hours so the live cultures have the best chance of survival. Many clinicians dose probiotics in the evening if antibiotics are morning-and-midday.
3. Continue probiotics for the full course and beyond. The benefit extends into the recovery period as the microbiome rebounds.
4. Discuss mastic gum with the prescribing doctor. Generally well-tolerated, but combinations with prescription regimens deserve a knowledgeable provider in the loop.
5. Avoid alcohol during the antibiotic course, particularly if metronidazole is in the regimen (the combination can produce a disulfiram-like reaction).

The Wang 2013 meta-analysis and McFarland 2015 S. boulardii meta-analysis both concluded that adjunctive probiotics improved tolerability and modestly improved eradication rates. Antibiotic-associated diarrhea, nausea, and taste disturbance are common during eradication; reducing them improves adherence, which improves outcomes.

The post-eradication protocol

This is the part of the conversation that gets the least attention and, in our view, matters most for long-term gut health. A 10–14 day course of multi-drug antibiotic therapy substantially disrupts the broader gut microbiome. Recovery takes weeks to months, and what you do during that window influences how completely the microbiome rebounds.

What the research suggests for the post-eradication period:

• Multi-strain probiotic support, daily. The post-antibiotic gut is a more open ecological niche — for beneficial repopulation and, unfortunately, opportunistic organisms. Daily probiotic intake helps tilt the balance toward beneficial recolonization. See our probiotic-after-antibiotics piece for the playbook.
• Prebiotic fiber. Beneficial bacteria need food. Soluble fiber from oats, legumes, alliums, and bananas supports regrowth.
• Dietary diversity. A wider variety of plant foods correlates with a more diverse, more resilient gut microbiome.
• Fermented foods. Yogurt, kefir, sauerkraut, kimchi, miso — live cultures add to dietary probiotic intake and fermentation byproducts feed native populations.
• Gut-lining support. Zinc carnosine, DGL, and L-glutamine have research for gastric mucosal integrity, particularly relevant after the inflammatory insult of both infection and therapy.

This is the window where Complete Gut Defense is designed to do its best work. Six clinically studied probiotic strains (including L. reuteri and S. boulardii), prebiotic FOS, mastic gum, and a broader nutrient profile map to exactly the kind of comprehensive post-eradication support the research suggests — daily, during and after antibiotic courses, under appropriate medical care.

Other supplements worth knowing

Beyond probiotics and mastic gum, a small handful of supportive nutrients have research worth knowing in the H. pylori and post-eradication context. None treat H. pylori; all may complement a guideline-directed approach.

• Zinc carnosine. A chelated form of zinc and L-carnosine studied for gastric mucosal integrity and ulcer healing, originally researched and approved in Japan. Supports mucus layer stability and may reduce reflux-related discomfort.
• DGL (deglycyrrhizinated licorice). Licorice with the glycyrrhizin removed to avoid blood pressure effects. Traditional use for gastric comfort and modest modern research for gastric mucus and stomach-lining integrity.
• Vitamin C. Observational research links higher dietary vitamin C with lower H. pylori infection rates and improved eradication outcomes. Food-first is the right framing — high-dose vitamin C on an empty stomach during active gastritis is not a good idea.

Supplement decisions during active eradication therapy belong in conversation with the prescribing doctor. Some (including high-dose iron) interact with the timing and absorption of the antibiotic regimen.

What not to do

The most important section of this article. There is a wellness-marketing industry built around supplement protocols positioned as alternatives to antibiotic eradication of H. pylori. They are inappropriate, and in some cases dangerous.

• Do not replace prescribed antibiotics with supplements alone. Mastic gum, broccoli sprouts, garlic extract, probiotics, oregano oil — none match the eradication efficacy of guideline-directed regimens, and untreated H. pylori is associated with peptic ulcer disease and increased gastric cancer risk.
• Do not skip retesting. The point of eradication therapy is eradication, not symptom improvement. Retesting (urea breath or stool antigen, 4–8 weeks after completing therapy) is the only way to confirm success.
• Do not stop antibiotics early because side effects appeared. Talk to the prescriber. Probiotic adjuncts often help. Premature discontinuation encourages resistance.
• Do not assume improved symptoms mean the infection is gone. Many people feel better before eradication is complete; some symptoms resolve even when the infection persists. The test is the test.
• Do not self-diagnose or self-treat. Upper-abdominal symptoms can be many things, including non-H. pylori causes. A gastroenterologist orders the right tests and interprets the results.

When to retest and the bottom line

Both the ACG (2017) and Maastricht VI (2022) guidelines recommend confirming eradication after completing therapy. The standard approach: wait at least 4 weeks after the antibiotic course ends, stop any PPI for 2 weeks prior, and retest using a urea breath or stool antigen test — both more reliable than antibody testing for confirming current infection. Residual antibiotic activity and PPI use both reduce H. pylori load enough to produce false negatives.

If the first eradication attempt fails (it happens, often due to clarithromycin resistance), the guidelines outline second-line and salvage regimens with different antibiotic combinations. Squarely a gastroenterologist’s call.

The honest bottom line: H. pylori is a real infection with real downstream risks, and the standard medical eradication regimens work in roughly 80–90% of cases when completed. Probiotics — particularly L. reuteri DSMZ 17648, L. johnsonii La1, and S. boulardii — have research supporting their use alongside antibiotics to improve eradication rates and reduce side effects. Mastic gum has modest but real evidence for upper-GI comfort and some H. pylori activity in small trials. The post-eradication window is where comprehensive microbiome support pays the largest dividends. None of this replaces a gastroenterologist; all of it can complement one. If you suspect H. pylori, the next step is a clinician visit and appropriate testing — not the supplement aisle. Once a treatment plan is in place, that’s when the adjunct conversation begins. For terminology, see our gut health glossary; related: heartburn and reflux overlap.